Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations-Reference-Cited by-同舟云学术

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

Published:2021-01 Issue:1 Volume:2 Page:100107
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Ninomiya Kiichiro,Teraoka Shunsuke,Zenke Yoshitaka,Kenmotsu Hirotsugu,Nakamura Yukiko,Okuma Yusuke,Tamiya Akihiro,Nosaki Kaname,Morise Masahiro,Aokage Keiju,Oya Yuko,Kozuki Toshiyuki,Sakamoto Tomohiro,Tanaka Kentaro,Tanaka Hisashi,Tanizaki Junko,Miura Satoru,Mizutani Hideaki,Miyauchi Eisaku,Yamaguchi Ou,Ebi Noriyuki,Goto Yasushi,Sasaki Takaaki,Daga Haruko,Morita Satoshi,Yamanaka Takeharu,Amano Shinsuke,Hasegawa Kazuo,Imamura Chiyo K.,Suzuki Kenichi,Nakajima Kazuko,Nishimoto Hitomi,Oizumi Satoshi,Hida Toyoaki,Hotta Katsuyuki,Takiguchi Yuichi

Funder

Japan Lung Cancer Society

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference56 articles.

1. Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV;Akamatsu;Int J Clin Oncol,2019

2. Use of the GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive;Jaeschke;BMJ,2008

3. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis;Lee;JAMA Oncol,2018

4. Osimertinib compared docetaxel-bevacizumab as a third-line treatment in EGFR T790M mutated non-small-cell lung cancer;Nie;Lung Cancer,2018

5. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study;Xu;Lung Cancer,2019

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722;Journal of Clinical Oncology;2024-04-10

2. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer;Cancer Science;2024-03-07

3. Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer;Cancer Medicine;2024-01

4. Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study;Journal of Personalized Medicine;2023-12-25

5. The 2022 Incentive Award of the Okayama Medical Association in Cancer Research (2022 Hayashibara Prize and Yamada Prize);Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2023-12-01